US 11,717,514 B2
PSMA binding ligand-linker conjugates and methods for using
Philip Stewart Low, West Lafayette, IN (US); and Sumith A. Kularatne, West Lafayette, IN (US)
Assigned to Purdue Research Foundation, West Lafayette, IN (US)
Filed by Purdue Research Foundation, West Lafayette, IN (US)
Filed on Oct. 30, 2020, as Appl. No. 17/86,063.
Application 17/086,063 is a continuation of application No. 15/990,152, filed on May 25, 2018, granted, now 10,828,282.
Application 15/990,152 is a continuation of application No. 15/606,913, filed on May 26, 2017, granted, now 10,406,240.
Application 15/606,913 is a continuation of application No. 14/794,482, filed on Jul. 8, 2015, granted, now 10,046,054.
Application 14/794,482 is a continuation of application No. 12/673,931, granted, now 9,193,763, previously published as PCT/US2008/073375, filed on Aug. 15, 2008.
Claims priority of provisional application 61/074,358, filed on Jun. 20, 2008.
Claims priority of provisional application 60/956,489, filed on Aug. 17, 2007.
Prior Publication US 2021/0077468 A1, Mar. 18, 2021
Int. Cl. A61K 31/426 (2006.01); A61K 47/54 (2017.01); A61K 49/00 (2006.01); C07K 5/08 (2006.01); A61K 31/4745 (2006.01); A61K 31/475 (2006.01); A61K 47/64 (2017.01); C07C 323/52 (2006.01); C07D 207/416 (2006.01); A61K 51/04 (2006.01); A61K 51/08 (2006.01)
CPC A61K 31/426 (2013.01) [A61K 31/475 (2013.01); A61K 31/4745 (2013.01); A61K 47/54 (2017.08); A61K 47/542 (2017.08); A61K 47/547 (2017.08); A61K 47/548 (2017.08); A61K 47/64 (2017.08); A61K 49/0041 (2013.01); A61K 49/0043 (2013.01); A61K 49/0052 (2013.01); A61K 49/0056 (2013.01); A61K 51/04 (2013.01); A61K 51/0402 (2013.01); A61K 51/0489 (2013.01); A61K 51/088 (2013.01); C07C 323/52 (2013.01); C07D 207/416 (2013.01); C07K 5/08 (2013.01)] 3 Claims
 
1. A compound of the formula:
B-L-IA
or a salt thereof, wherein:
B is a ligand of prostate specific membrane antigen (PSMA), wherein the ligand is a urea of two amino acids, wherein the two amino acids are independently selected from asparagine, aspartic acid, cysteine, glutamic acid, lysine, glutamine, arginine, serine, ornithine, and threonine;
L is a divalent linker of 14 to 24 atoms in length, wherein the divalent linker comprises chains of carbon and oxygen atoms forming a polyoxyalkylene group and a divalent peptide comprising a phenylalanine residue and a tyrosine residue; and
IA is a fluorescent imaging agent.